secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0000950170-23-008452
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta reports FY2022 net loss of $113.8M; cash $354.9M; NKX101/019 updates in 2023
--------------------------------------------------------------------------------

- Net loss of $113.8M ($2.61 diluted EPS) for FY2022; Q4 loss $32.6M ($0.67).
- Cash and investments total $354.9M; management expects runway to fund operations into 2025.
- R&D expenses $90.9M (FY) and $26.8M (Q4); G&A $28.1M (FY) and $8.1M (Q4).
- NKX101: 60% CR in AML at higher doses; additional data expected H1 2023.
- NKX019: 70% CR in B-cell malignancies; dose expansion enrolling; updated data expected in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017023008452/0000950170-23-008452-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017023008452/nktx-20230316.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-008452

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer